Olema Pharmaceuticals, Inc. OLMA EBITDA

EBITDA at other companies

Eli LillyLLY

$9.78B+34.8%

LON

LeonaBio, Inc.LONA

-$16.98M-82.8%

Oric Pharmaceuticals, Inc.ORIC

-$39.35M-21.4%

Opko HealthOPK

$15.44M+142%

Stoke Therapeutics, Inc.STOK

-$52.98M-147%

IDEAYA Biosciences, Inc.IDYA

-$107.86M-28.7%

FAQ

What is Olema Pharmaceuticals, Inc.'s EBITDA?

Olema Pharmaceuticals, Inc. (OLMA) reported EBITDA of -$57.87M in Q1 2026.

How has Olema Pharmaceuticals, Inc.'s EBITDA changed year-over-year?

Olema Pharmaceuticals, Inc.'s EBITDA decreased by 66.5% year-over-year, from -$34.75M to -$57.87M.

What is the long-term trend for Olema Pharmaceuticals, Inc.'s EBITDA?

Over 4 years (2021 to 2025), Olema Pharmaceuticals, Inc.'s EBITDA has grown at a 25.7% compound annual growth rate (CAGR), from -$71.33M to -$178.21M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.